Strategies and Barriers in mUC Maintenance Therapy

Video

Panel members share insights into strategies and barriers to maintenance therapy for patients with bladder cancer.

Related Videos
A panel of 5 experts on colorectal cancer
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
A panel of 5 experts on colorectal cancer
A panel of 5 experts on colorectal cancer
Related Content
Patients with muscle-invasive bladder cancer who remain molecular residual disease negative following cystectomy may be spared from adjuvant therapy.

MRD Negativity Status Following Surgery Confers Survival in MIBC

April 8th 2024
Article

Patients with muscle-invasive bladder cancer who remain molecular residual disease negative following cystectomy may be spared from adjuvant therapy.

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

Finding Ways to Break the Mold in GU Oncology

April 8th 2024
Podcast

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

Data from the phase 3 EV-302 trial support an application for enfortumab vedotin plus pembrolizumab as a treatment for patients with advanced bladder cancer in China.

Enfortumab Vedotin Combo Earns Priority Review in China for Bladder Cancer

March 29th 2024
Article

Data from the phase 3 EV-302 trial support an application for enfortumab vedotin plus pembrolizumab as a treatment for patients with advanced bladder cancer in China.

Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

Oncology Peer Review On-The-Go: Neoadjuvant Chemotherapy for Elderly Patients with Muscle-Invasive Bladder Cancer

March 15th 2022
Podcast

Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

Results from the phase 3 CHECKMATE-901 trial led to the approval of nivolumab plus cisplatin and gemcitabine for patients with unresectable or metastatic urothelial carcinoma.

FDA Approves First-line Nivolumab Combo for Urothelial Carcinoma

March 7th 2024
Article

Results from the phase 3 CHECKMATE-901 trial led to the approval of nivolumab plus cisplatin and gemcitabine for patients with unresectable or metastatic urothelial carcinoma.

Enfortumab Vedotin Combo Earns Priority Review in Japan for Bladder Cancer | Image Credit: © SciePro - stock.adobe.com.

Enfortumab Vedotin Combo Earns Priority Review in Japan for Bladder Cancer

February 19th 2024
Article

Data from the phase 3 EV-302 trial support the supplemental biologics license application for enfortumab vedotin plus pembrolizumab for patients with advanced or metastatic urothelial cancer in Japan.